Search Results - "JOY HO, P"

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma by Schuster, Stephen J, Bishop, Michael R, Tam, Constantine S, Waller, Edmund K, Borchmann, Peter, McGuirk, Joseph P, Jäger, Ulrich, Jaglowski, Samantha, Andreadis, Charalambos, Westin, Jason R, Fleury, Isabelle, Bachanova, Veronika, Foley, S. Ronan, Ho, P. Joy, Mielke, Stephan, Magenau, John M, Holte, Harald, Pantano, Serafino, Pacaud, Lida B, Awasthi, Rakesh, Chu, Jufen, Anak, Özlem, Salles, Gilles, Maziarz, Richard T

“…The capacity to use CAR T-cell therapy has been limited by the need to produce cells in a specialized laboratory. In this study, 40% of patients with relapsed…”
Get full text

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study by Bahlis, Nizar J., Dimopoulos, Meletios A., White, Darrell J., Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Ho, P. Joy, Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Kaufman, Jonathan L., Krevvata, Maria, Chiu, Christopher, Qin, Xiang, Okonkwo, Linda, Trivedi, Sonali, Ukropec, Jon, Qi, Ming, San-Miguel, Jesus

“…In POLLUX, daratumumab (D) plus lenalidomide/dexamethasone (Rd) reduced the risk of disease progression or death by 63% and increased the overall response rate…”
Get full text

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial by Fowler, Nathan Hale, Dickinson, Michael, Dreyling, Martin, Martinez-Lopez, Joaquin, Kolstad, Arne, Butler, Jason, Ghosh, Monalisa, Popplewell, Leslie, Chavez, Julio C., Bachy, Emmanuel, Kato, Koji, Harigae, Hideo, Kersten, Marie José, Andreadis, Charalambos, Riedell, Peter A., Ho, P. Joy, Pérez-Simón, José Antonio, Chen, Andy I., Nastoupil, Loretta J., von Tresckow, Bastian, Ferreri, Andrés José María, Teshima, Takanori, Patten, Piers E. M., McGuirk, Joseph P., Petzer, Andreas L., Offner, Fritz, Viardot, Andreas, Zinzani, Pier Luigi, Malladi, Ram, Zia, Aiesha, Awasthi, Rakesh, Masood, Aisha, Anak, Oezlem, Schuster, Stephen J., Thieblemont, Catherine

“…Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with…”
Get full text

Single-cell analysis of the CD8 + T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69 - subset suggesting potent cytotoxic effectors exist within the tumor bed by Favaloro, James, Bryant, Christian E, Abadir, Edward, Gardiner, Samuel, Yang, Shihong, King, Tracy, Nassif, Najah, Sedger, Lisa M, Boyle, Richard, Joshua, Douglas E, Ho, P Joy

“…Multiple myeloma (MM) is an incurable disease of the bone marrow (BM) characterized by the uncontrolled proliferation of neoplastic plasma cells. While CD8+ T…”
Get full text

Single-cell analysis of the T-cell receptor repertoire in untreated myeloma patients suggests potential myeloma-reactive CD8+ T-cells are shared between blood and marrow by Favaloro, James, Bryant, Christian E, Abadir, Edward, Gardiner, Samuel, Yang, Shihong, King, Tracy, Nassif, Najah, O'Brien, Bronwyn A, Sedger, Lisa M, Boyle, Richard, Joshua, Douglas E, Ho, P Joy

“…Not available.Not available…”
Get full text

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14) by Kalff, Anna, Khong, Tiffany, Ramachandran, Malarmathy, Ho, P Joy, Mollee, Peter, D'Rozario, James, Taylor, Kerry, Estell, Jane, Norton, Sam, Kemp, Roslyn, Mitchell, Andrew J, Reynolds, John, Kennedy, Nola, Quach, Hang, Spencer, Andrew

Get full text

Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1 by LING, Silvia C. W, LAU, Edwin K. K, JOSHUA, Douglas E, ALLEN, John D, AL-SHABEEB, Ammira, NIKOLIC, Angela, CATALANO, Albert, ILAND, Harry, HORVATH, Noemi, JOY HO, P, HARRISON, Simon, FLEMING, Shaun

“…Multiple myeloma, a malignancy of the antibody-secreting plasma cells, remains incurable by current therapy. However, the proteasome inhibitor bortezomib and…”
Get full text

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma by Facon, Thierry, Niesvizky, Ruben, Mateos, Maria-Victoria, Siegel, David, Rosenbaum, Cara, Bringhen, Sara, Weisel, Katja, Ho, P. Joy, Ludwig, Heinz, Kumar, Shaji, Wang, Kenneth, Obreja, Mihaela, Yang, Zhao, Klippel, Zandra, Mezzi, Khalid, Goldrick, Amanda, Tekle, Christina, Dimopoulos, Meletios A.

“…Frailty is most prevalent among elderly multiple myeloma (MM) patients, and frail patients have a higher risk of poor outcomes due to reduced performance…”
Get full text

CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis by Brown, Ross, Kabani, Karieshma, Favaloro, James, Yang, Shihong, Ho, P. Joy, Gibson, John, Fromm, Phillip, Suen, Hayley, Woodland, Narelle, Nassif, Najah, Hart, Derek, Joshua, Douglas

“…The transfer of membrane proteins between cells during contact, known as trogocytosis, can create novel cells with a unique phenotype and altered function. We…”
Get full text

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX by Kaufman, Jonathan L., Dimopoulos, Meletios A., White, Darrell, Benboubker, Lotfi, Cook, Gordon, Leiba, Merav, Morton, James, Joy Ho, P., Kim, Kihyun, Takezako, Naoki, Moreau, Philippe, Sutherland, Heather J., Magen, Hila, Iida, Shinsuke, Kim, Jin Seok, Miles Prince, H., Cochrane, Tara, Oriol, Albert, Bahlis, Nizar J., Chari, Ajai, O’Rourke, Lisa, Trivedi, Sonali, Casneuf, Tineke, Krevvata, Maria, Ukropec, Jon, Kobos, Rachel, Avet-Loiseau, Hervé, Usmani, Saad Z., San-Miguel, Jesus

“…High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated…”
Get full text

Inverse relationship between oligoclonal expanded CD69− TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients by Vuckovic, Slavica, Bryant, Christian E., Lau, Ka Hei Aleks, Yang, Shihong, Favaloro, James, McGuire, Helen M., Clark, Georgina, de St. Groth, Barbara Fazekas, Marsh-Wakefield, Felix, Nassif, Najah, Abadir, Edward, Vanguru, Vinay, McCulloch, Derek, Brown, Christina, Larsen, Stephen, Dunkley, Scott, Khoo, Liane, Gibson, John, Boyle, Richard, Joshua, Douglas, Ho, P. Joy

“…CD8+CD57+ terminal effector T (TTE) cells are a component of marrow-infiltrating lymphocytes and may contribute to the altered immune responses in multiple…”
Get full text

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission by Hsu, Jennifer L., Bryant, Christian E., Papadimitrious, Michael S., Kong, Benjamin, Gasiorowski, Robin E., Orellana, Daniel, McGuire, Helen M., Groth, Barbara Fazekas de St, Joshua, Douglas E., Ho, P. Joy, Larsen, Stephen, Iland, Harry J., Gibson, John, Clark, Georgina J., Fromm, Phillip D., Hart, Derek NJ

“…Only modest advances in AML therapy have occurred in the past decade and relapse due to residual disease remains the major challenge. The potential of the…”
Get full text

CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation by Abadir, Edward, Gasiorowski, Robin E., Lai, Kaitao, Kupresanin, Fiona, Romano, Adelina, Silveira, Pablo A., Lo, Tsun‐Ho, Fromm, Phillip D., Kennerson, Marina L., Iland, Harry J., Ho, P. Joy, Hogarth, P. Mark, Bradstock, Kenneth, Hart, Derek N.J., Clark, Georgina J.

“…Antibody‐based therapy in acute myeloid leukemia (AML) has been marred by significant hematologic toxicity due to targeting of both hematopoietic stem and…”
Get full text

Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemia by Abadir, Edward, Silveira, Pablo A., Gasiorowski, Robin E., Ramesh, Murari, Romano, Adelina, Mekkawy, Ahmed H., Lo, Tsun-Ho, Kabani, Karieshma, Sutherland, Sarah, Pietersz, Geoffrey A., Ho, P. Joy, Bryant, Christian E., Larsen, Stephen R., Clark, Georgina J.

“…Allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly reduces the rate of relapse in acute myeloid leukemia (AML) but comes at the cost…”
Get full text

Variation in immunoglobulin use and impact on survival in myeloma by Chai, Khai Li, Wellard, Cameron, Thao, LTP, Aoki, Naomi, Moore, Elizabeth M, Augustson, Bradley M, Bapat, Akshay, Blacklock, Hilary, Chng, Wee J, Cooke, Rachel, Forsyth, Cecily J, Goh, Yeow‐Tee, Hamad, Nada, Harrison, Simon J, Ho, P Joy, Hocking, Jay, Kerridge, Ian, Kim, Jin Seok, Kim, Kihyun, King, Tracy, McCaughan, Georgia J, Mollee, Peter, Morrissey, C Orla, Murphy, Nick, Quach, Hang, Tan, Xuan Ni, Tso, Allison CY, Wong, Kimberly SQ, Yoon, Sung‐Soo, Spencer, Andrew, Wood, Erica M, McQuilten, Zoe K

“…Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin…”
Get full text

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion‐dependent anemia: the TIMES study by Ho, P. Joy, Hiwase, Devendra, Ramakrishna, Raj, Viiala, Nicholas, Solterbeck, Ann, Traficante, Robert, Zor, Evren, Gervasio, Othon L., High, Laura M., Ross, David M., Bowden, Donald K.

“…Supplemental Digital Content is available in the text The significant morbidity and mortality associated with iron overload can be reduced by effective iron…”
Get full text

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study by Schuster, Stephen J, Tam, Constantine S, Borchmann, Peter, Worel, Nina, McGuirk, Joseph P, Holte, Harald, Waller, Edmund K, Jaglowski, Samantha, Bishop, Michael R, Damon, Lloyd E, Foley, Stephen Ronan, Westin, Jason R, Fleury, Isabelle, Ho, P Joy, Mielke, Stephan, Teshima, Takanori, Janakiram, Murali, Hsu, Jing-Mei, Izutsu, Koji, Kersten, Marie José, Ghosh, Monalisa, Wagner-Johnston, Nina, Kato, Koji, Corradini, Paolo, Martinez-Prieto, Marcela, Han, Xia, Tiwari, Ranjan, Salles, Gilles, Maziarz, Richard T

“…In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best…”
Get full text

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma by Sonneveld, Pieter, Dimopoulos, Meletios A., Boccadoro, Mario, Quach, Hang, Ho, P. Joy, Beksac, Meral, Hulin, Cyrille, Antonioli, Elisabetta, Leleu, Xavier, Mangiacavalli, Silvia, Perrot, Aurore, Cavo, Michele, Belotti, Angelo, Broijl, Annemiek, Gay, Francesca, Mina, Roberto, Nijhof, Inger S., van de Donk, Niels W.C.J., Katodritou, Eirini, Schjesvold, Fredrik, Sureda Balari, Anna, Rosiñol, Laura, Delforge, Michel, Roeloffzen, Wilfried, Silzle, Tobias, Vangsted, Annette, Einsele, Hermann, Spencer, Andrew, Hajek, Roman, Jurczyszyn, Artur, Lonergan, Sarah, Ahmadi, Tahamtan, Liu, Yanfang, Wang, Jianping, Vieyra, Diego, van Brummelen, Emilie M.J., Vanquickelberghe, Veronique, Sitthi-Amorn, Anna, de Boer, Carla J., Carson, Robin, Rodriguez-Otero, Paula, Bladé, Joan, Moreau, Philippe

“…The addition of subcutaneous daratumumab to bortezomib, lenalidomide, and dexamethasone therapy and to lenalidomide maintenance therapy had a significant…”
Get full text

Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma by Brown, Ross, Suen, Hayley, Favaloro, James, Yang, Shihong, Ho, P. Joy, Gibson, John, Joshua, Douglas

“…Trogocytosis, which results in the acquisition of myeloma cell-derived membrane proteins by T cells, and hence generates novel regulatory T cells, adds to the…”
Get full text

Benign clinical phenotype of co‐inherited congenital dyserythropoietic anaemia type I and heterozygous haemoglobin Lepore by Li, Eric Wenlong, Walsh, Rebecca, Ho, P. Joy

Get full text